好色先生

好色先生

Explore the latest content from across our publications

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Demographic and Clinical Characteristics of Patients Treated with Natalizumab in Post-Marketing Setting. A Prospective Multicenter Observational Study of 1000 Patients
MS and Related Diseases
(-)
072
Authors/Disclosures
No disclosure on file
No disclosure on file
Christine Lebrun Frenay, MD, FAAN (CRCSEP Neurologie) Dr. Lebrun Frenay has received personal compensation in the range of $0-$499 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Revue Neurologique. The institution of Dr. Lebrun Frenay has received research support from FRANCE SEP.
Marc Debouverie, MD (Hospital Central) Dr. Debouverie has nothing to disclose.
Philippe Cabre, MD (CHU Martinique) No disclosure on file
Christian Confavreux, MD (Hospital Antiquaille) No disclosure on file
Jean Pelletier, MD, PhD (Dpt of Neurology, CHU Timone) Dr. Pelletier has nothing to disclose.
William Camu, MD (Centre Gui de Chauliac) No disclosure on file
Ayman P. Tourbah (Department of Neurology University Hospital Raymond Poincaré) No disclosure on file
Pierre Clavelou, MD, PhD (Hopital Gabriel Montpied) Dr. Clavelou has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Novartis. Dr. Clavelou has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Janssen. Dr. Clavelou has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Merck.
Olivier Casez, MD (CHU De Grenoble) Dr. Casez has nothing to disclose.
Patrick Hautecoeur (Centre Hospitalier Saint Philibert) No disclosure on file
Gilles Edan, MD No disclosure on file
Didier Ferriby, MD (Clinique Neurologique/Neuro D) No disclosure on file
Roland Liblau Roland Liblau has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Merck. Roland Liblau has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Novartis. Roland Liblau has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Biogen. Roland Liblau has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Sanofi-genzyme. Roland Liblau has received personal compensation in the range of $0-$499 for serving on a Speakers Bureau for Servier. Roland Liblau has received personal compensation in the range of $0-$499 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Current Opinion in Immunology. The institution of Roland Liblau has received research support from Roche. The institution of Roland Liblau has received research support from ARSEP. The institution of Roland Liblau has received research support from Fondation pour la Recherche Médicale. The institution of Roland Liblau has received research support from Population Bio UK, Inc. The institution of Roland Liblau has received research support from ANR.
Michel G. Clanet, Prof No disclosure on file
No disclosure on file